论文部分内容阅读
目的检测膜联蛋白A5(ANXA5)在人宫颈鳞癌患者外周血中的含量改变,探讨ANXA5作为宫颈癌诊断标志物的可行性。方法收集人宫颈鳞癌患者外周血清48例和正常育龄妇女外周血清38例,低速离心取上清,采用酶联免疫吸附测定(ELISA)法分别检测血清中ANXA5和鳞状细胞癌抗原(SCCAg)的含量;离心后取红细胞行RT-PCR进行患者与正常组ANXA5表达的检测。组间检验采用t检验;并进行肿瘤患者中ANXA5与SCCAg的相关性分析。结果宫颈鳞癌患者血清中ANXA5的含量均比正常人显著增多,血细胞中ANXA5mRNA的表达显著增多,差异有显著性(P<0.05);SCCAg在肿瘤组中的含量同样显著高于正常组(P<0.05);ANXA5与SCCAg具有明显的相关性,但ANXA5的阳性率大于SCCAg。结论 ANXA5在宫颈鳞癌患者外周血中含量增高,特异性和敏感性较高,可作为临床诊断和预后宫颈鳞癌的备选标志物。
Objective To detect the changes of the content of annexin A5 (ANXA5) in the peripheral blood of patients with cervical squamous cell carcinoma and to explore the feasibility of ANXA5 as a diagnostic marker of cervical cancer. Methods Serum levels of ANXA5 and SCCAg were detected by enzyme-linked immunosorbent assay (ELISA) in 48 cases of peripheral blood serum of patients with cervical squamous cell carcinoma and 38 cases of peripheral blood of normal women of childbearing age. After centrifugation, erythrocytes were collected and RT-PCR was performed to detect the expression of ANXA5 in patients and normal controls. Group test using t test; and cancer patients ANXA5 and SCCAg correlation analysis. Results The serum levels of ANXA5 in patients with cervical squamous cell carcinoma were significantly higher than those in normal controls, and the expression of ANXA5 mRNA in blood cells was significantly increased (P <0.05). The content of SCCAg in the tumor group was also significantly higher than that in the normal group <0.05). There was a significant correlation between ANXA5 and SCCAg, but the positive rate of ANXA5 was higher than that of SCCAg. Conclusion ANXA5 in peripheral blood of patients with cervical squamous cell carcinoma increased, specificity and sensitivity, and can be used as an alternative marker for clinical diagnosis and prognosis of cervical squamous cell carcinoma.